{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) 3.1 vs 1.0 Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination creates broader antigen display by expanding the fraction of tumor proteins represented in the immunopeptidome.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6% Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
          "line_ref": "L11"
        }
      ],
      "caveat": "The combination effect was tested in murine models; translation to human tumors requires prospective validation."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving immune checkpoint inhibitor treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value p=0.01 Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; vaccination timing relative to ICI initiation varied across patients; tumor-type mix and treatment-history heterogeneity limit direct causal interpretation."
    },
    {
      "claim_id": "C05",
      "claim": "Combined intratumoral mRNA vaccination and checkpoint blockade increases CD8+ T-cell infiltration in tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    }
  ]
}
